Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line

Biochemical and Biophysical Research Communications

Volumn 377, Issue 2, 2008, Pages 489-494

  Ekerljung, Lina ^a   Lindborg, Malin ^b   Gedda, Lars ^a   Frejd, Fredrik Y ^b   Carlsson, Jörgen ^a   Lennartsson, Johan ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecule; Akt; Erk; HER2; Proliferation; Trastuzumab

Indexed keywords

(Z HER2:342)2; (Z HER2:4)2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BIOSENSOR; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN SKBR 3; CELL STRAIN SKOV 3; CONTROLLED STUDY; CYTOLYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BIOSENSING TECHNIQUES; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DIMERIZATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 55549120512     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.027     Document Type: Article

References (22)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
2. Tyson F.L., Boyer C.M., Kaufman R., O'Briant K., Cram G., Crews J.R., Soper J.T., Daly L., Fowler Jr. W.C., Haskill J.S., et al. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am. J. Obstet. Gynecol. 165 (1991) 640-646
3. Chen J.S., Lan K., and Hung M.C. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist. Updat. 6 (2003) 129-136
4. Marmor M.D., Skaria K.B., and Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 903-913
5. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney Jr. D.W., and Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
6. Carlsson J., Nordgren H., Sjostrom J., Wester K., Villman K., Bengtsson N.O., Ostenstad B., Lundqvist H., and Blomqvist C. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br. J. Cancer 90 (2004) 2344-2348
7. Nygren P.A. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 275 (2008) 2668-2676
8. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., Sandstrom M., Rosik D., Carlsson J., Lundqvist H., Wennborg A., and Nilsson F.Y. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule. Cancer Res. 67 (2007) 2773-2782
9. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Hoiden-Guthenberg I., Widstrom C., Carlsson J., Tolmachev V., Stahl S., and Nilsson F.Y. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66 (2006) 4339-4348
10. Nilsson F.Y., and Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discov. Devel. 10 (2007) 167-175
11. Steffen A.C., Orlova A., Wikman M., Nilsson F.Y., Stahl S., Adams G.P., Tolmachev V., and Carlsson J. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 631-638
12. Orlova A., Tolmachev V., Pehrson R., Lindborg M., Tran T., Sandstrom M., Nilsson F.Y., Wennborg A., Abrahmsen L., and Feldwisch J. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 67 (2007) 2178-2186
13. Ekerljung L., Steffen A.C., Carlsson J., and Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol. 27 (2006) 201-210
14. Aguilar Z., Akita R.W., Finn R.S., Ramos B.L., Pegram M.D., Kabbinavar F.F., Pietras R.J., Pisacane P., Sliwkowski M.X., and Slamon D.J. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18 (1999) 6050-6062
15. Lennartsson J., Blume-Jensen P., Hermanson M., Ponten E., Carlberg M., and Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18 (1999) 5546-5553
16. Steffen A.C., Wikman M., Tolmachev V., Adams G.P., Nilsson F.Y., Stahl S., and Carlsson J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother. Radiopharm. 20 (2005) 239-248
17. Bao J.J., Le X.F., Wang R.Y., Yuan J., Wang L., Atkinson E.N., LaPushin R., Andreeff M., Fang B., Yu Y., and Bast Jr. R.C. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res. 62 (2002) 7264-7272
18. Longva K.E., Pedersen N.M., Haslekas C., Stang E., and Madshus I.H. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 116 (2005) 359-367
19. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., and Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17 (1998) 2235-2249
20. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., van de Vijver M.J., and Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402
21. Diermeier S., Horvath G., Knuechel-Clarke R., Hofstaedter F., Szollosi J., and Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp. Cell Res. 304 (2005) 604-619
22. Rahmouni S., Cerignoli F., Alonso A., Tsutji T., Henkens R., Zhu C., Louis-dit-Sully C., Moutschen M., Jiang W., and Mustelin T. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat. Cell Biol. 8 (2006) 524-531